Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS(G12C)-Driven Mouse Model of Lung Cancers

PURPOSE: Despite the challenge to directly target mutant KRAS due to its high GTP affinity, some agents are under development against downstream signaling pathways, such as MEK inhibitors. However, it remains controversial whether MEK inhibitors can boost current chemotherapy in KRAS-mutant lung tum...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Li, Shuai, Liu, Shengwu, Deng, Jiehui, Akbay, Esra A., Hai, Josephine, Ambrogio, Chiara, Zhang, Long, Zhou, Fangyu, Jenkins, Russell W., Adeegbe, Dennis O., Gao, Peng, Wang, Xiaoen, Paweletz, Cloud P., Herter-Sprie, Grit S., Chen, Ting, Gutiérrez-Quiceno, Laura, Zhang, Yanxi, Merlino, Ashley A., Quinn, Max M., Zeng, Yu, Yu, Xiaoting, Liu, Yuting, Fan, Lichao, Aguirre, Andrew J., Barbie, David A., Yi, Xianghua, Wong, Kwok-Kin
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482448/
https://ncbi.nlm.nih.gov/pubmed/29945997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3438
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi